Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 Takeout Price
Medivation Advises Its Shareholders To Spurn Sanofi's Move To Replace Entire Board
Barclays Lays Out Its Sum-Of-The-Parts Analysis On Medivation, Boosts Target Price By $22
Medivation's Take-Out Price Raised To $68-$78 At Citi
Xtandi Recent News
If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi's Bid
Stifel Lays Out 3 Scenarios For Medivation Takeover
Jefferies Lifts Target On Medivation To $52 From $39 As 'Xtandi Looking Better'
Here's What Medivation Said In Its Rejection Letter To Sanofi
Leerink: Medivation Buyout 'Inevitable,' AstraZeneca And AbbVie Most Likely Buyers
SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position
Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price
Medivation Up As Triple M&A Interest Rumor Circulates
LifeSci Capital's Andrew McDonald On How To Invest In Booming Biotech
Citigroup Adds Tesaro To 'Focus List,' Removes Medivation